XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 3 Months Ended
Jun. 29, 2024
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
16. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker.

The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and
operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
Three Months Ended
(In thousands)June 29,
2024		July 1,
2023
Net revenues(1)
Plasma$136,042 $139,491 
Blood Center66,839 69,169 
Hospital134,406 102,428 
Net revenues in constant currency337,287 311,088 
Effect of exchange rates(1,115)244 
Net revenues$336,172 $311,332 
(1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Three Months Ended
(In thousands)June 29,
2024		July 1,
2023
Segment operating income
Plasma$65,837 $75,698 
Blood Center22,622 26,283 
Hospital53,891 40,943 
Segment operating income142,350 142,924 
Corporate expenses (1)
(69,980)(75,309)
Effect of exchange rates(1,349)2,613 
Amortization of acquired intangible assets(12,471)(7,473)
Amortization of fair value inventory step-up(5,239)— 
Integration and transaction costs(12,323)(1,115)
Restructuring costs(4,622)11 
Restructuring related costs(2,518)(2,204)
Digital transformation costs(6,345)(3,705)
Impairment of assets and PCS2 related charges— 141 
MDR and IVDR costs(1,126)(1,166)
Litigation-related charges(755)(1,058)
Gain on sale of property, plant and equipment14,134 — 
Operating income$39,756 $53,659 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Net revenues by business unit are as follows:
  Three Months Ended
(In thousands)June 29,
2024		July 1,
2023
 Plasma$135,910 $139,621 
Apheresis49,094 49,166 
Whole Blood17,151 20,040 
 Blood Center66,245 69,206 
Interventional Technologies(1)
63,044 37,620 
Blood Management Technologies(2)
70,973 64,885 
 Hospital134,017 102,505 
Net revenues(3)
$336,172 $311,332 
(1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
(2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
(3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.

Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
Three Months Ended
(In thousands)June 29,
2024		July 1,
2023
United States$248,902 $237,073 
Japan13,705 11,773 
Europe47,225 39,387 
Rest of Asia19,783 22,040 
Other6,557 1,059 
Net revenues$336,172 $311,332